Please Upload related files below
Fill in below.
Tell us the stocks you own using Snaptrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. Snaptrade only shares the tickers you own and your transaction history, not your account numbers. Using Snaptrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery- link your account with Snaptrade.
On May 18, 2020, Moderna announced encouraging preliminary results from the National Institute for Allergy and Infectious Diseases (“NIAID”)’s Phase 1 trial of the Company’s Covid-19 vaccione candidate, mRNA-1273. Following the announcement, Moderna’s stock price spiked nearly 20%.
However, the next day, the health news website STAT published an article casting doubt on the prudence of the Company’s optimism and highlighting the lack of key data in Moderna’s statements. Specifically, the article stated that vaccine experts had concluded that “there’s really no way to know how impressive — or not — the vaccine may be.”
Following the article, Moderna’s stock price plummeted, closing at $57.71 per share on May 27, 2020, even lower than Moderna was trading prior to the announcement of positive preliminary results. Further, related news articles have leveled accusations of insider trading against Moderna executives.